On 2025‑10‑20, Kairos Pharma Ltd. (NYSE American: KAPA) presented interim efficacy data from its Phase 2 trial of ENV‑105 (carotuximab) in combination with apalutamide to the European Society of Medical Oncology (ESMO) in Berlin. The presentation, delivered by Chief Scientific Officer Dr. Neil Bhowmick and trial director Edwin Posadas, highlighted the first‑in‑class CD105 antagonist’s performance in men with metastatic castration‑resistant prostate cancer (mCRPC).
The data showed that 86% of the 13 evaluable patients experienced clinical benefit, with a median progression‑free survival (PFS) of 13.7 months. Seven of nine patients had a reduction in prostate‑specific antigen (PSA) levels, and half of the responders remained progression‑free beyond one year. These results build on the safety profile previously reported and suggest that ENV‑105 can restore sensitivity to hormone therapy in a population that has progressed on standard treatments.
The interim efficacy findings reinforce Kairos Pharma’s mechanistic rationale and may accelerate discussions with regulatory authorities. By demonstrating durable disease control and PSA suppression, the company strengthens its case for continued development of ENV‑105 and positions the asset as a potential breakthrough in the mCRPC therapeutic landscape. The trial is enrolling up to 100 patients across Cedars‑Sinai, City of Hope, and Huntsman Cancer Institute, underscoring the company’s expanding clinical footprint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.